Table of Content

1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Overview
1.1 Product Overview and Scope of Antisense oligonucleotides (ASO) Drug and siRNA Drug
1.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Type
1.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Value Comparison by Type (2024-2034)
1.2.2 Antisense Oligonucleotides (ASO) Drug
1.2.3 siRNA Drug
1.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Application
1.3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Value by Application: (2024-2034)
1.3.2 Single Gene Rare Disease
1.3.3 Protein Deposition Disease
1.3.4 Chronic Liver Disease
1.3.5 Others
1.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Estimates and Forecasts
1.4.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue 2018-2029
1.4.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales 2018-2029
1.4.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Competition by Manufacturers
2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Manufacturers (2018-2024)
2.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Product Type & Application
2.7 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Competitive Situation and Trends
2.7.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antisense oligonucleotides (ASO) Drug and siRNA Drug Players Market Share by Revenue
2.7.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Retrospective Market Scenario by Region
3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region: 2018-2029
3.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region: 2018-2024
3.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region: 2024-2029
3.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region: 2018-2029
3.3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region: 2018-2024
3.3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region: 2024-2029
3.4 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Facts & Figures by Country
3.4.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2029)
3.4.3 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Facts & Figures by Country
3.5.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2029)
3.5.3 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Facts & Figures by Country
3.7.1 Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2029)
3.7.3 Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2029)
4.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2018-2024)
4.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Type (2024-2029)
4.1.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2018-2029)
4.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2029)
4.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2018-2024)
4.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2024-2029)
4.2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2018-2029)
4.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2029)
5.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2018-2024)
5.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Application (2024-2029)
5.1.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2018-2029)
5.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2029)
5.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2018-2024)
5.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2024-2029)
5.2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2018-2029)
5.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Alnylam
6.1.1 Alnylam Corporation Information
6.1.2 Alnylam Description and Business Overview
6.1.3 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.1.5 Alnylam Recent Developments/Updates
6.2 Ionis
6.2.1 Ionis Corporation Information
6.2.2 Ionis Description and Business Overview
6.2.3 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.2.5 Ionis Recent Developments/Updates
6.3 Biogen
6.3.1 Biogen Corporation Information
6.3.2 Biogen Description and Business Overview
6.3.3 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.3.5 Biogen Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Sarepta Therapeutics
6.5.1 Sarepta Therapeutics Corporation Information
6.5.2 Sarepta Therapeutics Description and Business Overview
6.5.3 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.5.5 Sarepta Therapeutics Recent Developments/Updates
6.6 Therapeutics
6.6.1 Therapeutics Corporation Information
6.6.2 Therapeutics Description and Business Overview
6.6.3 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.6.5 Therapeutics Recent Developments/Updates
6.7 Akcea
6.6.1 Akcea Corporation Information
6.6.2 Akcea Description and Business Overview
6.6.3 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.7.5 Akcea Recent Developments/Updates
6.8 WAVElife
6.8.1 WAVElife Corporation Information
6.8.2 WAVElife Description and Business Overview
6.8.3 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.8.5 WAVElife Recent Developments/Updates
6.9 ProQR
6.9.1 ProQR Corporation Information
6.9.2 ProQR Description and Business Overview
6.9.3 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.9.4 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.9.5 ProQR Recent Developments/Updates
6.10 Exicure
6.10.1 Exicure Corporation Information
6.10.2 Exicure Description and Business Overview
6.10.3 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.10.5 Exicure Recent Developments/Updates
6.11 Secarna
6.11.1 Secarna Corporation Information
6.11.2 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.11.3 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.11.5 Secarna Recent Developments/Updates
6.12 AstraZeneca
6.12.1 AstraZeneca Corporation Information
6.12.2 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.12.3 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.12.4 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.12.5 AstraZeneca Recent Developments/Updates
6.13 The WhiteOak Group, Inc.
6.13.1 The WhiteOak Group, Inc. Corporation Information
6.13.2 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.13.3 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.13.4 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.13.5 The WhiteOak Group, Inc. Recent Developments/Updates
6.14 Dicerna
6.14.1 Dicerna Corporation Information
6.14.2 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.14.3 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.14.5 Dicerna Recent Developments/Updates
6.15 Silence
6.15.1 Silence Corporation Information
6.15.2 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.15.3 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.15.5 Silence Recent Developments/Updates
6.16 Arrowhead
6.16.1 Arrowhead Corporation Information
6.16.2 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.16.3 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.16.4 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.16.5 Arrowhead Recent Developments/Updates
6.17 Miragen Therapeutics
6.17.1 Miragen Therapeutics Corporation Information
6.17.2 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.17.3 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.17.4 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.17.5 Miragen Therapeutics Recent Developments/Updates
6.18 Genzyme
6.18.1 Genzyme Corporation Information
6.18.2 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.18.3 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.18.4 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.18.5 Genzyme Recent Developments/Updates
6.19 Quark Pharmaceuticals
6.19.1 Quark Pharmaceuticals Corporation Information
6.19.2 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.19.3 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.19.4 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.19.5 Quark Pharmaceuticals Recent Developments/Updates
6.20 Sylentis
6.20.1 Sylentis Corporation Information
6.20.2 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.20.3 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.20.4 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.20.5 Sylentis Recent Developments/Updates
6.21 Avidity Biosciences
6.21.1 Avidity Biosciences Corporation Information
6.21.2 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Description and Business Overview
6.21.3 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales, Revenue and Gross Margin (2018-2024)
6.21.4 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
6.21.5 Avidity Biosciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Chain Analysis
7.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Mode & Process
7.4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales and Marketing
7.4.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Channels
7.4.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Distributors
7.5 Antisense oligonucleotides (ASO) Drug and siRNA Drug Customers
8 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Dynamics
8.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends
8.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Drivers
8.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Challenges
8.4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Product Type & Application
Table 12. Global Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2018-2024) & (K Units)
Table 18. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2018-2024)
Table 19. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2024-2029) & (K Units)
Table 20. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2024-2029)
Table 21. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2024) & (K Units)
Table 27. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2024-2029) & (K Units)
Table 28. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2024) & (K Units)
Table 32. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2024-2029) & (K Units)
Table 33. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units) by Type (2018-2024)
Table 51. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units) by Type (2024-2029)
Table 52. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2018-2024)
Table 53. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Type (2024-2029)
Table 54. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price (US$/Unit) by Type (2018-2024)
Table 59. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price (US$/Unit) by Type (2024-2029)
Table 60. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units) by Application (2018-2024)
Table 61. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units) by Application (2024-2029)
Table 62. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2018-2024)
Table 63. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Application (2024-2029)
Table 64. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2018-2024)
Table 67. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2024-2029)
Table 68. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price (US$/Unit) by Application (2018-2024)
Table 69. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price (US$/Unit) by Application (2024-2029)
Table 70. Alnylam Corporation Information
Table 71. Alnylam Description and Business Overview
Table 72. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 74. Alnylam Recent Developments/Updates
Table 75. Ionis Corporation Information
Table 76. Ionis Description and Business Overview
Table 77. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 79. Ionis Recent Developments/Updates
Table 80. Biogen Corporation Information
Table 81. Biogen Description and Business Overview
Table 82. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 84. Biogen Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 89. Novartis Recent Developments/Updates
Table 90. Sarepta Therapeutics Corporation Information
Table 91. Sarepta Therapeutics Description and Business Overview
Table 92. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 94. Sarepta Therapeutics Recent Developments/Updates
Table 95. Therapeutics Corporation Information
Table 96. Therapeutics Description and Business Overview
Table 97. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 99. Therapeutics Recent Developments/Updates
Table 100. Akcea Corporation Information
Table 101. Akcea Description and Business Overview
Table 102. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 104. Akcea Recent Developments/Updates
Table 105. WAVElife Corporation Information
Table 106. WAVElife Description and Business Overview
Table 107. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 109. WAVElife Recent Developments/Updates
Table 110. ProQR Corporation Information
Table 111. ProQR Description and Business Overview
Table 112. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 114. ProQR Recent Developments/Updates
Table 115. Exicure Corporation Information
Table 116. Exicure Description and Business Overview
Table 117. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 119. Exicure Recent Developments/Updates
Table 120. Secarna Corporation Information
Table 121. Secarna Description and Business Overview
Table 122. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 124. Secarna Recent Developments/Updates
Table 125. AstraZeneca Corporation Information
Table 126. AstraZeneca Description and Business Overview
Table 127. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 129. AstraZeneca Recent Developments/Updates
Table 130. The WhiteOak Group, Inc. Corporation Information
Table 131. The WhiteOak Group, Inc. Description and Business Overview
Table 132. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 134. The WhiteOak Group, Inc. Recent Developments/Updates
Table 135. Dicerna Corporation Information
Table 136. Dicerna Description and Business Overview
Table 137. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 139. Dicerna Recent Developments/Updates
Table 140. Silence Corporation Information
Table 141. Silence Description and Business Overview
Table 142. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 143. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 144. Silence Recent Developments/Updates
Table 145. Arrowhead Corporation Information
Table 146. Arrowhead Description and Business Overview
Table 147. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 148. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 149. Arrowhead Recent Developments/Updates
Table 150. Miragen Therapeutics Corporation Information
Table 151. Miragen Therapeutics Description and Business Overview
Table 152. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 153. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 154. Miragen Therapeutics Recent Developments/Updates
Table 155. Genzyme Corporation Information
Table 156. Genzyme Description and Business Overview
Table 157. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 158. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 159. Genzyme Recent Developments/Updates
Table 160. Quark Pharmaceuticals Corporation Information
Table 161. Quark Pharmaceuticals Description and Business Overview
Table 162. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 163. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 164. Quark Pharmaceuticals Recent Developments/Updates
Table 165. Sylentis Corporation Information
Table 166. Sylentis Description and Business Overview
Table 167. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 168. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 169. Sylentis Recent Developments/Updates
Table 170. Avidity Biosciences Corporation Information
Table 171. Avidity Biosciences Description and Business Overview
Table 172. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 173. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
Table 174. Avidity Biosciences Recent Developments/Updates
Table 175. Key Raw Materials Lists
Table 176. Raw Materials Key Suppliers Lists
Table 177. Antisense oligonucleotides (ASO) Drug and siRNA Drug Distributors List
Table 178. Antisense oligonucleotides (ASO) Drug and siRNA Drug Customers List
Table 179. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Trends
Table 180. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Drivers
Table 181. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Challenges
Table 182. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Antisense oligonucleotides (ASO) Drug and siRNA Drug
Figure 2. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Type in 2022 & 2029
Figure 4. Antisense Oligonucleotides (ASO) Drug Product Picture
Figure 5. siRNA Drug Product Picture
Figure 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application in 2022 & 2029
Figure 8. Single Gene Rare Disease
Figure 9. Protein Deposition Disease
Figure 10. Chronic Liver Disease
Figure 11. Others
Figure 12. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2018-2029) & (US$ Million)
Figure 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (2018-2029) & (K Units)
Figure 15. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price (US$/Unit) & (2018-2029)
Figure 16. Antisense oligonucleotides (ASO) Drug and siRNA Drug Report Years Considered
Figure 17. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Share by Manufacturers in 2022
Figure 18. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Antisense oligonucleotides (ASO) Drug and siRNA Drug Players: Market Share by Revenue in 2022
Figure 20. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Country (2018-2029)
Figure 23. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Country (2018-2029)
Figure 24. United States Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Country (2018-2029)
Figure 27. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Country (2018-2029)
Figure 28. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Region (2018-2029)
Figure 35. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Country (2018-2029)
Figure 43. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Country (2018-2029)
Figure 44. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Market Share by Country (2018-2029)
Figure 48. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Country (2018-2029)
Figure 49. Turkey Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Global Sales Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type (2018-2029)
Figure 53. Global Revenue Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type (2018-2029)
Figure 54. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price (US$/Unit) by Type (2018-2029)
Figure 55. Global Sales Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Application (2018-2029)
Figure 56. Global Revenue Market Share of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Application (2018-2029)
Figure 57. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Price (US$/Unit) by Application (2018-2029)
Figure 58. Antisense oligonucleotides (ASO) Drug and siRNA Drug Value Chain
Figure 59. Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed